Article | Published:

HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions

Abstract

In this study, we evaluate the expression of human papillomavirus E4 protein (marker for the onset of a productive infection) and hypermethylation of host-cell CADM1, MAL, and miR124-2 genes (marker for an advanced, transforming infection) in cervical intraepithelial neoplasia (CIN) and cancer. A total of 115 cervical lesions were categorized by 3 pathologists into no dysplasia, CIN1, CIN2, CIN3, or cancer by classical histomorphological grading criteria, and by an immunoscore (cumulative value: 0–6) grading system based on Ki-67 (score: 0–3) and p16ink4a (score: 0–3) expression. Lesions were immunostained for E4 protein and analyzed for hypermethylation of CADM1, MAL, or miR124-2 genes. Expression of E4 and hypermethylation levels were related to CIN grade based on both classical and immunoscore grading. Hypermethylation increased with severity of the lesion as defined by both classical histomorphological grading and immunoscore criteria, and was always present in carcinomas (22/22). Extensive E4 expression decreased with increasing CIN grade and immunoscore, being most frequent in classically graded CIN1 or in lesions with cumulative immunoscore 1–3 and absent in carcinomas. High-grade lesions (CIN2/3 or immunoscore: 4–6) showed less E4 expression, which was inversely related to an increasing hypermethylation. Extensive E4 expression, as observed in a small proportion of high-grade lesions (6/49 and 8/43, respectively), was mostly associated with a negative methylation marker status (5/6 and 7/8, respectively). Our results illustrate the gradual transition of productive CIN (reflected by extensive E4 expression), to advanced transforming CIN (reflected by extensive hypermethylation) and cancer. Expression patterns of E4 and hypermethylation status of host-cell genes, may be used to identify cervical lesions at risk for cervical cancer, providing a better guidance for clinicians on treatment decisions.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Wright TW, Ronnett BM, Kurman RJ, Ferenczy A, Kurman RJ, Ellenson LH. et al. Blaustein’s Pathology of the Female Genital Tract. Bosten, MA: Springer; 2011. 2011:193–252.

  2. 2.

    van Baars R, Griffin H, Wu Z, et al. Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by combining the novel molecular biomarker PanHPVE4 with P16INK4a. Am J Surg Pathol. 2015;39:1518–28.

  3. 3.

    Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186–92.

  4. 4.

    Baak JP, Kruse AJ, Robboy SJ, et al. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol. 2006;59:1017–28.

  5. 5.

    Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113:18–25.

  6. 6.

    van Zummeren M, Leeman A, Kremer WW, et al. A three-tiered score for Ki-67 and p16ink4a improves accuracy and reproducibility of grading CIN lesions. J Clin Pathol. In press.

  7. 7.

    Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis. 2012;16:205–42.

  8. 8.

    Herrington CS. The terminology of pre-invasive cervical lesions in the UK cervical screening programme. Cytopathology. 2015;26:346–50.

  9. 9.

    Heatley MK. How should we grade CIN? Histopathology. 2002;40:377–90.

  10. 10.

    Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. Br Med J. 2014;349:g6192.

  11. 11.

    Doorbar J, Quint W, Banks L, et al. The biology and life cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–70.

  12. 12.

    Griffin H, Soneji Y, Van Baars R, et al. Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM. Mod Pathol. 2015;28:977–93.

  13. 13.

    Doorbar J. The E4 protein; structure, function and patterns of expression. Virology. 2013;445:80–98.

  14. 14.

    Overmeer RM, Henken FE, Snijders PJ, et al. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol. 2008;215:388–97.

  15. 15.

    Overmeer RM, Henken FE, Bierkens M, et al. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol. 2009;219:327–36.

  16. 16.

    Wilting SM, van Boerdonk RA, Henken FE, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010;9:167.

  17. 17.

    Overmeer RM, Louwers JA, Meijer CJ, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer. 2011;129:2218–25.

  18. 18.

    De Strooper LM, Meijer CJ, Berkhof J, et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev Res (Phila). 2014;7:1251–7.

  19. 19.

    Verlaat W, Snijders PJ, Novianti PW, et al. Genome-wide DNA methylation profiling reveals methylation markers associated with 3q gain for detection of cervical pre-cancer and cancer. Clin Cancer Res. 2017;23:3813–22.

  20. 20.

    Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009;112:293–9.

  21. 21.

    Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14:395–405.

  22. 22.

    Luttmer R, De Strooper LM, Steenbergen RD, et al. Management of high-risk HPV-positive women for detection of cervical (pre)cancer. Expert Rev Mol Diagn. 2016;16:961–74.

  23. 23.

    De Strooper LM, van Zummeren M, Steenbergen RD, et al. CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol. 2014;67:1067–71.

  24. 24.

    Van Zummeren M, Kremer WW, Van Aardt MC, et al. Selection of women at risk for cervical cancer in an HIV-infected SOUTH AFRICAN population. AIDS. 2017;31:1945–53.

  25. 25.

    Bierkens M, Hesselink AT, Meijer CJ, et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer. 2013;133:1293–9.

  26. 26.

    Federation of Biomedical Scientific Societies. Human Tissue and Medical Research: Code of Conduct for responsible use. https://www.federa.org/sites/default/files/images/print_version_code_of_conduct_english.pdf (2011).

  27. 27.

    van den Brule AJ, Pol R, Fransen-Daalmeijer N, et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40:779–87.

  28. 28.

    Sie D, Snijders PJ, Meijer GA, et al. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr). 2014;37:353–61.

  29. 29.

    Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23.

  30. 30.

    Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Prim. 2016;2:16086.

  31. 31.

    Griffin H, Wu Z, Marnane R, et al. E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. PLoS ONE. 2012;7:e49974.

  32. 32.

    Burgers WA, Blanchon L, Pradhan S, et al. Viral oncoproteins target the DNA methyltransferases. Oncogene. 2007;26:1650–5.

  33. 33.

    Snellenberg S, De Strooper LM, Hesselink AT, et al. Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. BMCw Cancer. 2012;12:551–9.

  34. 34.

    van Baars R, van der Marel J, Snijders PJ, et al. CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies. Int J Cancer. 2016;138:463–71.

  35. 35.

    van der Marel J, van Baars R, Rodriguez A, et al. The increased detection of cervical intraepithelial neoplasia when using a second biopsy at colposcopy. Gynecol Oncol. 2014;135:201–7.

  36. 36.

    Wentzensen N, Walker JL, Gold MA, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015;33:83–9.

Download references

Acknowledgments

We gratefully acknowledge the research staff and technicians of the Department of Pathology VUmc.

Author information

Correspondence to Chris J. L. M. Meijer.

Ethics declarations

Conflict of interest

(1) D.A.M.H., P.J.F.S., R.D.M.S., and C.J.L.M.M. are minority shareholders of self-screen B.V., a spin-off company of VUmc; (2) self-screen B.V. holds patents related to the work (i.e., hrHPV test and methylation markers for cervical screening); (3) D.A.M.H. has been on the speaker's bureau of Qiagen and serves occasionally on the scientific advisory boards of Pfizer and Bristol-Meyers Squibb; (4) P.J.F.S. has been on the speakers bureau of Roche diagnostics, Gen-Probe, Abbott, Qiagen and Seegene and has been a consultant for Crucell B.V.; (5) J.B. received consultancy fees from Roche, GlaxoSmithKline, and Merck and received travel support from DDL. All fees were collected by his employer; (6) C.J.L.M.M. served occasionally on the scientific advisory board (expert meeting) of Qiagen and SPMSD/Merck, and has by occasion been consultant for Qiagen; he has been co- investigator on a Sanofi Pasteur/MSD sponsored HPV vaccination trial in men of which his institute received research funding; (7) C.J.L.M.M. has small number of shares of Qiagen, is minority shareholder of Self-Screen bv of which he is part-time director since sept 2017. He was minority shareholder of Diassay B.V. until April 2016; (8) M.V.Z., W.W.K., A.L., M.C.G.B., D.J., J.D., and G.G.K. declare that they have no conflict of interest.

Additional information

Deceased: Peter J. F. Snijders

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Fig. 1
Fig. 2
Fig. 3